Biofuels & Biobased Earnings Roundup: Amyris
by Jim Lane
The Top Line. In California, Amyris (AMRS) reported Q2 GAAP revenue for the second quarter of 2018 of $24.8 million, compared with $25.7 million for the second quarter of 2017. Grants and collaborations revenue was $11.4 million for the second quarter of 2018 compared with $10.3 million for the year-ago period. The company noted that Q2 revenue was $24.8 million compared with the same period in 2017 of $21.7 million when adjusted for the low margin product sales on contracts assigned to DSM (DSM.AS). This reflects 15% growth on an absolute basis. GAAP net loss for the first half was $89.1...
The Return of Advanced Biofuels
by Jim Lane
For several years now we have seen a significant number of players pivoting from biofuels towards smaller but higher-value markets in chemicals, nutrition, nutraceuticals, pharma, materials, flavorings, fragrances, cosmetics and more. We’ve reported on the proliferation of applications both in the Digest and in What’s Nuu? and indeed there’s been so much that’s Nuu, it’s been dizzying at times with all the spinning and twirling.
Capital costs and policy uncertainty have played their part, but the foot on the pedal for many has been oil prices. The scale of operations to compete with oil prices in the 2014-2017 period...
Biofuels & Biobased Earnings Roundup: Corbion
by Jim Lane
The Top Line. In the Netherlands, Corbion (CRBN.AS; CSNVY) reported H1 2018 sales of € 439.2 million, a decrease of 4.9% compared to H1 2017, entirely due to negative currency effects. Organic sales growth was 3.1%. EBITDA excluding one-off items in H1 2018 decreased by 19.0% to € 71.5 million due to negative currency effects and the inclusion of the Algae Ingredients business. Organic EBITDA excluding one-off items increased by 1.2% in H1 2018.
The Big Highlights. The acquisition of the Algae Ingredients business (TerraVia assets + SB Renewable Oils joint venture) has added an algae fermentation platform to Corbion. In H1 2018,...
Living Endangeredly- Q2 Biobased Earnings Roundup
by Jim Lane
In hand we now have the latest earnings reports from what you might call the 8 Pathfinders – eight publicly traded stocks whose second quarter results offer insights into the health and performance of the advanced bioeconomy as 2019 heads towards its closing crescendos.
Our 8 Pathfinders – In the world of global renewable diesel at scale, Neste (Neste.HE); pure-play enzymes, Novozymes (NVMB); In pharma and synbio, Codexis (CDXS); as a hybrid play in advanced fuels, Aemetis (AMTX); in advanced marine and jet fuels, Gevo (GEVO); for biodiesel and hydrocarbons, Renewable Energy Group (REGI); in advanced began foods,...
Gevo’s Glow
Specialty chemicals developer Gevo, Inc. (GEVO: Nasdaq) is celebrating a string of market wins for its renewable chemicals and fuels. Since its beginning thirteen years ago this month, Gevo has been doggedly perfecting its synthetic biology and chemical technologies and turning it into products that are in demand by consumers and industry. Last week shareholders were treated to an announcement by the U.S. Environmental Protection Agency (EPA) raising the amount of isobutanol for on-road use to 16% blend level from 12.5%. As a producer of renewable isobutanol Gevo will be a direct beneficiary of the EPA action. Following directly on the heels of that news,...
Corbion Bids To Acquire TerraVia
Corbion Bids To Acquire TerraVia
In California, Corbion has made a $20M stalking horse stock and asset purchase bid for TerraVia (TRVA).
The purchase agreement provides TerraVia with a binding bid of $20 million in cash along with the assumption of certain liabilities, which is subject to higher or otherwise better offers. As part of the transaction, Corbion will be assuming the ongoing financial obligations of the business and its joint venture ownership, therefore the total financial commitment is expected to be in excess of the cash purchase price. Through this proposed transaction, TerraVia employees, who bring with them a wide...
Gevo Begins To Ship Missing Link For 100% Renewable Plastic Bottles
Jim Lane From Colorado, news has arrived that Gevo (GEVO) is now selling paraxyleme to Toray (TRYIF), one of the world’s leading producers of fibers, plastics, films, and chemicals. It’s producing PX from isobutanol, one of its three molecules in production (the others are jet fuel and iso-ocrane) at its complex in Silsbee, Texas. Toray expects to produce fibers, yarns, and films from Gevo’s PX. While any new molecule attached to a major customer relationship is always big news for any producer this has special significance. Let’s review exactly why....
Biofuels & Biobased Earnings Roundup: DSM
by Jim Lane
The Top Line. In the Netherlands, Royal DSM (Amsterdam: DSM.AS; US OTC:KDSKF; US ADR:RDSMY) reported a good H1 with organic sales growth in underlying business estimated at 10% and adjusted EBITDA growth of underlying business estimated at 7%, with sales of €4,794 million and adjusted EBITDA of €771 million.
The Big Highlights. Nutrition: an estimated 8% underlying organic sales growth and Adjusted EBITDA growth of underlying business estimated at 6%. Materials: 7% organic sales growth and Adjusted EBITDA growth of 5%. DSM also confirmed its full year outlook 2018, as provided at Q1 2018, and expects an Adjusted EBITDA growth towards...
Solazyme’s Detours on the Way to Algae Biofuel
by Debra Fiakas CFA Investors who took the time to read my last two posts on algae-based biofuel – “Algae Takes Flight” and “Emission Standards Driving Aviation Fuel Sourcing” - might have wondered why there was no mention of Solazyme, Inc. (SZYM: Nasdaq). California-based Solazyme has been pursuing algae-based oils for transportation since 2004, and managed to record its first product sales in 2011. However, that revenue was not from biofuel. On the long road to finding a scalable and efficient way to get renewable fuel from algae, Solazyme scientists found an interesting extract...
Amyris: 90 Days To Build The Future
Jim Lane In California, Amyris (AMRS) reported Q1 revenues of $13.0M compared with $8.8M for Q1 2016, and touted the “significant increase in product sales, primarily in the personal care and health and nutrition markets, offset by a slight decline in collaboration revenue.” Collaboration revenues contributed $4.7M and product sales added $8.3M for the quarter. Big Q1 miss vs analyst expectations As Jeff Osborne at Cowen & Co noted, “Amyris reported revenue of $13.0mn, well below our estimate of $37.1mn due to much lower collaboration payments than we had anticipated. Management has highlighted that these payments can...
New Bio-Based Tacky Resins Launched With Amyris Technology
Jim Lane In France, Cray Valley has launched new tackifying resins produced with Amyris’ (AMRS) biologically derived Biofene branded farnesene. Tack is the measure of stickiness vital to everything from adhesives that need to hold things in place to inks that need to stay on the printed page. According to independent market research firm, MarketsandMarkets.com, the global tackifier market is projected to reach USD 3.56 billion by 2020. This poses a large opportunity for renewable farnesene-based tackifiers and Amyris believes it can access a large market share as its product applications within the space achieve commercial scale. Cray...
Amyris, Cosan JV Launches 100% Renewable Base Oils
Jim Lane Portrait of a breakout: Amyris (AMRS), Cosan (CZZ) JV Novii launches “next generation of revolutionary oils” touting “unmatched value” and “unbeatable economics” In California, Novvi unveiled two new 100 percent renewable base oil products, a 100 percent renewable polyalphaolefin (PAO) Group IV and a 100 percent renewable version of its NovaSpec Group III+ base oil. Both will be manufactured at the company’s production facility in Houston. Base oils are blended with additives to make the engine oils and lubricants sold on the market today. So, here’s the technical scoop. Novvi’s 100 percent renewable...
Jobs at Gevo
by Debra Fiakas CFA Management teams at the helm of public companies often shade the realities of their competitive or strategic situation, alternately painting better circumstances or downplaying declining fortunes. There are myriad ways of giving management’s guidance a reality check. Renewable bio-chemicals developer Gevo, Inc. (GEVO: Nasdaq) is on my “watch list” as one of the more interesting companies in the Beach Boys Index. Gevo’s financial results missed the consensus estimate in both the March and June 2012 quarters, but management made claims of important victories. Gevo has won important decisions in the disagreement...
Bioplastics Maker Avantium’s IPO Plans
Jim Lane Here’s our 10-minute version of the filing, slightly re-organized to make sense to Earthlings instead of aliens from the Planet Prospectus. In the Netherlands, bioplastics maker Avantium is planning an initial public offering and listing of all shares on Euronext Amsterdam and Euronext Brussels. The company expects to raise up to €100 million (USD$106 million) and complete the offering by the end of the current quarter. More than half of the offering has already been secured via commitments from cornerstone investors. Avantium’s YXY technology converts plant-based sugar into chemicals and plastics, including 2,5-furandicarboxylic acid, a precursor...
Amyris: The New Colossus Aims To Unlock Its Golden Door
Jim Lane In California, Amyris (AMRS) reported a Q2 net loss of $13.8M on revenues of $9,6M, up from $7.8M in Q2 2015. Revenues rose 27% from the corresponding period in 2015 primarily driven by the shipment of a new novel fragrance product, as well as Neossance Squalane sales. At the same time, Amyris, which has recorded $18.4M in revenues for the first half, re-affirmed guidance for the year that it would reach $90M in annual sales and positive cash flow from operations in 2017. With that, Amyris would have increased revenues by 400% in the second half,...
Amryris: Zombie With Attitude
Jim Lane
Zombies with attitude. New partnerships for making magic molecules and exploitin’ the heck out of ’em.
These days, nothing in Hollywood beats a great zombie movie, more than 50 have been released in recent years. Zombies rise from the dead, and change everything around them. It’s not always pretty, or predictable, but they’re a disruptive force.
Well, Amyris (AMRS) is proving to be a zombie story these days starting with being labeled a “zombie company” by The Motley Fool. TMF writes:
Amyris was a pioneering industrial biotech that went from darling of the field to a company now trading well...
